Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis

Domestic Animal Endocrinology

Volumn 36, Issue 1, 2009, Pages 32-44

  Teshima, Takahiro ^a   Hara, Yasushi ^a   Takekoshi, Susumu ^b   Nezu, Yoshinori ^a   Harada, Yasuji ^a   Yogo, Takuya ^a   Teramoto, Akira ^c   Osamura, Robert Y ^b   Tagawa, Masahiro ^a  

^a Division of Veterinary Surgery   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Corticotroph; Cushing's disease; Dog; Nelson's syndrome; Trilostane

Indexed keywords

ANDROSTANOLONE; ANTINEOPLASTIC AGENT; CORTICOTROPIN; CORTICOTROPIN RECEPTOR; DRUG DERIVATIVE; HYDROCORTISONE; MESSENGER RNA; PROOPIOMELANOCORTIN; TRILOSTANE;

ACTH SECRETING CELL; ADRENAL GLAND; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DOG; DRUG ANTAGONISM; DRUG EFFECT; FEEDBACK SYSTEM; FEMALE; GENETICS; HYPERPLASIA; HYPOPHYSIS; HYPOTHALAMUS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SECRETION; ULTRASTRUCTURE;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTINEOPLASTIC AGENTS; CORTICOTROPHS; DIHYDROTESTOSTERONE; DOGS; FEEDBACK, BIOCHEMICAL; FEMALE; HYDROCORTISONE; HYPERPLASIA; HYPOTHALAMUS; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY GLAND; PRO-OPIOMELANOCORTIN; RECEPTORS, CORTICOTROPIN; RNA, MESSENGER;

ANIMALIA; CANIS FAMILIARIS;

EID: 57149132935     PISSN: 07397240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.domaniend.2008.10.002     Document Type: Article

References (65)

1. Guptill L., Scott-Moncrieff J.C., and Widmer W.R. Diagnosis of canine hyperadrenocorticism. Vet Clin North Am Small Anim Pract 27 (1997) 215-235
2. Feldman E.C., and Nelson R.W. Canine hyperadrenocorticism (Cushing's syndrome). In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), WB Saunders Co., Philadelphia 252-357
3. Hanson J.M., van't H.M., Voorhout G., Teske E., Kooistra H.S., and Meij B.P. Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 19 (2005) 687-694
4. Hanson J.M., Teske E., Voorhout G., Galac S., Kooistra H.S., and Meij B.P. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg 107 (2007) 830-840
5. Hara Y., Tagawa M., Masuda H., Sako T., Koyama H., Orima H., et al. Transsphenoidal hypophysectomy for four dogs with pituitary ACTH-producing adenoma. J Vet Med Sci 65 (2003) 801-804
6. Braddock J.A. Medical treatment of hyperadrenocorticism in the dog. Aust Vet J 81 (2003) 31-33
7. Bell R., Neiger R., McGrotty Y., and Ramsey I.K. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Vet Rec 159 (2006) 277-281
8. Alenza D.P., Arenas C., Lopez M.L., and Melian C. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc 42 (2006) 269-276
9. Braddock J.A., Church D.B., Robertson I.D., and Watson A.D. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 81 (2003) 600-607
10. Barker E.N., Campbell S., Tebb A.J., Neiger R., Herrtage M.E., Reid S.W., et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 19 (2005) 810-815
11. Reine N.J. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. Clin Tech Small Anim Pract 22 (2007) 18-25
12. Neiger R., Ramsey I., O'Connor J., Hurley K.J., and Mooney C.T. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 150 (2002) 799-804
13. Potts G.O., Creange J.E., Hardomg H.R., and Schane H.P. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 32 (1978) 257-267
14. Plumb D.C. Trilostane. In: Plumb D.C. (Ed). Veterinary drug handbook. 5th ed. (2005), Iowa State University Press, Ames 778-779
15. Peterson M.E. Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease). Vet Clin North Am Small Anim Pract 31 (2001) 1005-1014
16. Kintzer P.P., and Peterson M.E. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 5 (1991) 182-190
17. den Hertog E., Braakman J.C., Teske E., Kooistra H.S., and Rijnberk A. Results of non-selective adrenocorticolysis by o,p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 144 (1999) 12-17
18. Witt A.L., and Neiger R. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy. Vet Rec 154 (2004) 399-400
19. Sieber-Ruckstuhl N.S., Boretti F.S., Wenger M., Maser-Gluth C., and Reusch C.E. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane. Domest Anim Endocrinol 31 (2006) 63-75
20. Wenger M., Sieber-Ruckstuhl N.S., Müller C., and Reusch C.E. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 65 (2004) 1245-1250
21. Ruckstuhl N.S., Nett C.S., and Reusch C.E. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 63 (2002) 506-512
22. Hansen B.L., Kemppainen R.J., and MacDonald J.M. Synthetic ACTH (cosyntropin) stimulation tests in normal dogs: comparison of intravenous and intramuscular administration. J Am Anim Hosp Assoc 30 (1994) 38-41
23. Meij B.P., Mol J.A., Bevers M.M., and Rijnberk A. Residual pituitary function after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 155 (1997) 531-539
24. Reusch C.E., Steffen T., and Hoerauf A. The efficacy of l-deprenyl in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 13 (1999) 291-301
25. Fracassi F., Gandini G., Diana A., Preziosi R., Ingh T.S., Famigli-Bergamini P., et al. Acromegaly due to a somatroph adenoma in a dog. Domest Anim Endocrinol 32 (2007) 43-54
26. Granger N., de Fornel P., Devauchelle P., Segond S., Delisle F., and Rosenberg D. Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease. J Vet Intern Med 19 (2005) 23-28
27. Scott-Moncrieff J.C., Koshko M.A., Brown J.A., Hill K., and Refsal K.R. Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol 32 (2003) 180-187
28. Kooistra H.S., Voorhout G., Mol J.A., and Rijnberk A. Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 152 (1997) 387-394
29. Meij B.P., Mol J.A., van den Ingh T.S., Bevers M.M., Hazewinkel H.A., and Rijnberk A. Assessment of pituitary function after transsphenoidal hypophysectomy in beagle dogs. Domest Anim Endocrinol 14 (1997) 81-97
30. Taoda T., Hara Y., Takekoshi S., Itoh J., Teramoto A., Osamura R.Y., et al. Effect of mitotane on pituitary corticotrophs in clinically normal dogs. Am J Vet Res 67 (2006) 1385-1394
31. Sieber-Ruckstuhl N.S., Meli M.L., Boretti F.S., Gönczi E., Lutz H., and Reusch C.E. Quantitative real-time PCR for the measurement of 11beta-HSD1 and 11beta-HSD2 mRNA levels in tissues of healthy dogs. Horm Metab Res 39 (2007) 548-554
32. Brinkhof B., Spee B., Rothuizen J., and Penning L.C. Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 356 (2006) 36-43
33. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 18 3 (2002) [RESEARCH0034]
34. Keller-Wood M.E., and Dallman M.F. Corticosteroid inhibition of ACTH secretion. Endocr Rev 5 (1984) 1-24
35. Bertoy E.H., Feldman E.C., Nelson R.W., Dublin A.B., Reid M.H., and Feldman M.S. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 208 (1996) 1268-1273
36. Nelson R.W., Feldman E.C., and Shinsako J. Effect of o,p'DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism. Am J Vet Res 46 (1985) 1534-1537
37. Peterson M.E., Orth D.N., Halmi N.S., Zielinski A.C., Davis D.R., Chavez F.T., et al. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal concentrations. Endocrinology 119 (1986) 720-730
38. Sarfaty D., Carrillo J.M., and Peterson M.E. Neurologic, endocrinologic, and pathologic findings associated with large pituitary tumors in dogs: eight cases (1976-1984). J Am Vet Med Assoc 193 (1988) 854-856
39. Nelson D.H., Meakin J.W., Dealy Jr. J.B., Matson D.D., Emerson Jr. K., and Thorn G.W. ACTH-producing tumor of the pituitary gland. N Engl J Med 259 (1958) 161-164
40. Nelson D.H., Meakin J.W., and Thorn G.W. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med 52 (1960) 560-569
41. Kelly W.F., MacFarlane I.A., Longson D., Davies D., and Sutcliffe H. Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients. Q J Med 52 (1983) 224-231
42. Barnett A.H., Livesey J.H., Friday K., Donald R.A., and Espiner E.A. Comparison of preoperative and postoperative ACTH concentrations after bilateral adrenalectomy in Cushing's disease. Clin Endocrinol 18 (1983) 301-305
43. Thomas J.P., and Hall R. Medical management of pituitary disease. Clin Endocrinol Metab 12 (1983) 771-788
44. Kasperlik-Załuska A.A., Nielubowicz J., Wisławski J., Hartwig W., Załuska J., Jeske W., et al. Nelson's syndrome: incidence and prognosis. Clin Endocrinol 19 (1983) 693-698
45. Thomas Jr. C.G., Smith A.T., Benson M., and Griffith J. Nelson's syndrome after Cushing's disease in childhood: a continuing problem. Surgery 96 (1984) 1067-1077
46. Pereira M.A., Halpern A., Salgado L.R., Mendonça B.B., Nery M., Liberman B., et al. A study of patients with Nelson's syndrome. Clin Endocrinol 49 (1998) 533-539
47. Gil-Cárdenas A., Herrera M.F., Díaz-Polanco A., Rios J.M., and Pantoja J.P. Nelson's syndrome after bilateral adrenalectomy for Cushing's disease. Surgery 141 (2007) 147-152
48. Assié G., Bahurel H., Coste J., Silvera S., Kujas M., Dugué M.A., et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 92 (2007) 172-179
49. Assié G., Bahurel H., Bertherat J., Kujas M., Legmann P., and Bertagna X. The Nelson's syndrome ... revisited. Pituitary 7 (2004) 209-215
50. Teramoto A. Diagnosis and treatment of Cushing's disease. Jpn J Neurosurg 10 (2001) 86-91
51. Asa S.L., and Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19 (1998) 798-827
52. Suda T., Tomori N., Tozawa F., Mouri T., Demura H., and Shizume K. Effects of bilateral adrenalectomy on immunoreactive corticotropin-releasing factor in the rat median eminence and intermediate-posterior pituitary. Endocrinology 113 (1983) 1182-1184
53. Scheithauer B.W., Kovacs K., and Randall R.V. The pituitary gland in untreated Addison's disease. A histologic and immunocytologic study of 18 adenohypophyses. Arch Pathol Lab Med 107 (1983) 484-487
54. Gertz B.J., Contreras L.N., McComb D.J., Kovacs K., Tyrrell J.B., and Dallman M.F. Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology 120 (1987) 381-388
55. Mountjoy K.G., Bird I.M., Rainey W.E., and Cone R.D. ACTH induces up-regulation of ACTH receptor mRNA in mouse and human adrenocortical cell lines. Mol Cell Endocrinol 99 (1994) R17-R20
56. Penhoat A., Jaillard C., and Saez J.M. Corticotropin positively regulates its own receptors and cAMP response in cultured bovine adrenal cells. Proc Natl Acad Sci U S A 86 (1989) 4978-4981
57. Lebrethon M.C., Naville D., Begeot M., and Saez J.M. Regulation of corticotropin receptor number and messenger RNA in cultured human adrenocortical cells by corticotropin and angiotensin II. J Clin Invest 93 (1994) 1828-1833
58. Kijima H., Kubo M., Shimizu C., Ishizuka T., Takano K., Nagai S., et al. Effects of hypophysectomy and in vivo administration of ACTH or dexamethasone on the level of ACTH receptor mRNA in adrenal glands and adipose tissues of mice. Endocr Regul 38 (2004) 87-95
59. Reusch C.E., Sieber-Ruckstuhl N., Wenger M., Lutz H., Perren A., and Pospischil A. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane. Vet Rec 160 (2007) 219-224
60. Mantis P., Lamb C.R., Witt A.L., and Neiger R. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Vet Radiol Ultrasound 44 (2003) 682-685
61. Lambert F., Corcelle-Cerf F., Lammerant J., and Kolanowski J. On the specificity of the inhibitory effect of trilostane and aminoglutethimide on adrenocortical steroidogenesis in guinea pig. Mol Cell Endocrinol 37 (1984) 115-120
62. Chapman P.S., Kelly D.F., Archer J., Brockman D.J., and Neiger R. Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism. J Small Anim Pract 45 (2004) 307-310
63. Mack R.E., and Feldman E.C. Comparison of two low-dose dexamethasone suppression protocols as screening and discrimination tests in dogs with hyperadrenocorticism. J Am Vet Med Assoc 197 (1990) 1603-1606
64. Feldman E.C. Evaluation of a six-hour combined dexamethasone suppression/ACTH stimulation test in dogs with hyperadrenocorticism. J Am Vet Med Assoc 189 (1986) 1562-1566
65. Feldman E.C., Nelson R.W., and Feldman M.S. Use of low- and high-dose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc 209 (1996) 772-775